Background. Positive sentinel lymph node (SLN) findings in ductal carcinoma in situ (DCIS) range from 1 to 22 % but have unknown biologic significance. This study sought to identify predictors of positive SLNs and to assess their clinical significance for patients with an initial diagnosis of DCIS. Methods. The study identified 1234 patients with an initial diagnosis of DCIS who underwent SLN dissection (SLND) at our institution from 1997 through 2011. Positive SLN findings were categorized as isolated tumor cells (ITCs) (B0.2 mm), micrometastases ([0.2-2 mm), or macrometastases ([2 mm). Predictors of positive SLNs were analyzed, and survival outcomes were examined. Results. Positive SLN findings were identified in 132 patients (10.7 %): 66 patients with ITCs (5.4 %), 36 patients with micrometastases (2.9 %), and 30 patients with macrometastases (2.4 %). Upstaging to microinvasive (n = 68, 5.5 %) or invasive (n = 259, 21.0 %) cancer occurred for 327 patients (26.5 %). Factors predicting positive SLNs included diagnosis by excisional biopsy (odds ratio [OR] 1.90; P = 0.007), papillary histology (OR 1.77; P = 0.006), DCIS larger than 2 cm (OR 1.55; P = 0.030), more than three interventions before SLND (4 interventions: OR 2.04; P = 0.022; C5 interventions: OR 3.87; P \ 0.001), and occult invasion (microinvasive: OR 3.44; P = 0.001; invasive: OR 6.21; P \ 0.001). The median follow-up period was 61.7 months. Patients who had pure DCIS with and without positive SLNs had equivalent survival rates (100.0 vs 99.7 %; P = 0.679). Patients with occult invasion and positive SLNs had the worst survival rate (91.7 %; P \ 0.001). Conclusions. Occult invasion and more than three total interventions were the strongest predictors of positive SLN findings in patients with an initial diagnosis of DCIS. This supports the theory of benign mechanical transport of breast epithelial cells. Except for patients at high risk for invasive disease, routine use of SLND in DCIS is not warranted.
ABSTRACT
Background. Positive sentinel lymph node (SLN) findings in ductal carcinoma in situ (DCIS) range from 1 to 22 % but have unknown biologic significance. This study sought to identify predictors of positive SLNs and to assess their clinical significance for patients with an initial diagnosis of DCIS. Methods. The study identified 1234 patients with an initial diagnosis of DCIS who underwent SLN dissection (SLND) at our institution from 1997 through 2011. Positive SLN findings were categorized as isolated tumor cells (ITCs) (B0.2 mm), micrometastases ([0.2-2 mm), or macrometastases ([2 mm). Predictors of positive SLNs were analyzed, and survival outcomes were examined. Results. Positive SLN findings were identified in 132 patients (10.7 %): 66 patients with ITCs (5.4 %), 36 patients with micrometastases (2.9 %), and 30 patients with macrometastases (2.4 %). Upstaging to microinvasive (n = 68, 5.5 %) or invasive (n = 259, 21.0 %) cancer occurred for 327 patients (26.5 %) . Factors predicting positive SLNs included diagnosis by excisional biopsy (odds ratio [OR] 1.90; P = 0.007), papillary histology (OR 1.77; P = 0.006), DCIS larger than 2 cm (OR 1.55; P = 0.030), more than three interventions before SLND (4 interventions: OR 2.04; P = 0.022; C5 interventions: OR 3.87; P \ 0.001), and occult invasion (microinvasive: OR 3.44; P = 0.001; invasive: OR 6.21; P \ 0.001). The median follow-up period was 61.7 months. Patients who had pure DCIS with and without positive SLNs had equivalent survival rates (100.0 vs 99.7 %; P = 0.679). Patients with occult invasion and positive SLNs had the worst survival rate (91.7 %; P \ 0.001).
Conclusions. Occult invasion and more than three total interventions were the strongest predictors of positive SLN findings in patients with an initial diagnosis of DCIS. This supports the theory of benign mechanical transport of breast epithelial cells. Except for patients at high risk for invasive disease, routine use of SLND in DCIS is not warranted.
Due to widespread implementation of screening mammography, the reported incidence of ductal carcinoma in situ (DCIS) has increased. By definition, DCIS lacks the ability to metastasize, and early series in which the axilla was evaluated by axillary lymph node dissection (ALND) showed a metastases rate lower than 1 %. 1 However, in the sentinel lymph node (SLN) era, during which fewer nodes are resected and subjected to serial sectioning and often subjected to immunohistochemical evaluation, the reported incidence of positive SLNs in DCIS ranges from 1 to 22 %. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] The majority of these findings are isolated tumor cells (ITCs) or small-volume findings. [2] [3] [4] 7, 14 Benign mechanical transport of cells through the lymphatics due to preoperative manipulation of the primary tumor has been cited as a potential reason for positive lymph node findings. [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] It also is possible that a positive SLN reflects true metastatic disease in patients with a preoperative diagnosis of DCIS found to have occult invasion at the time of definitive surgery. This surgical upstaging has led some to advocate SLN dissection (SLND) for DCIS patients deemed to be at high risk for an invasive component or for patients for whom total mastectomy is planned. [30] [31] [32] The biologic significance of positive SLN findings in patients with DCIS is largely unknown, and whether clinicians should change management in response to positive SLN findings is debated. The current study sought to identify predictors of positive SLN findings and to assess their clinical significance in a cohort of patients with an initial diagnosis of DCIS who underwent SLND.
METHODS
The Breast Surgical Oncology Database at The University of Texas MD Anderson Cancer Center was queried to identify 2918 patients with an initial diagnosis of DCIS treated from 1997 through 2011, including 1386 patients who underwent SLND. The study excluded patients with concurrent contralateral invasive breast cancer (n = 96, 6.9 %), a history of prior ipsilateral breast cancer (n = 40, 2.9 %), or failed SLND (n = 16, 1.2 %). The result was a final study population of 1234 patients. The study was approved by the Institutional Review Board.
Sentinel Lymph Node Dissection
The patients underwent SLND at the discretion of the treating surgeon. The reasons for performing SLND in patients with DCIS included planned mastectomy and the presence of features suggesting a high risk for an invasive component (high grade, DCIS size [2 cm, palpable tumor, microinvasion suspected on biopsy). The reason for SLND was generally cited by the operating surgeon in the operative report. However, preoperative breast imaging results and pathology results also were used to determine all potential tumor characteristics that prompted the use of SLND.
In this study, SLND was performed using filtered technetium (Tc) 99 m-labeled sulfur colloid alone, 1 % isosulfan blue dye alone (Lymphazurin; US Surgical Corp., Norwalk, CT, USA), or a combination of these agents. 33 Dual tracers were used in 58.8 % (725/1234) of the patients. Mapping agents were injected subdermally, subareolarly, or peritumorally. An injection of 99m Tc-labeled sulfur colloid was administered the day before surgery (2.5 mCi) or on the day of surgery (0.5 mCi). At the time of surgery, blue dye was injected at a volume of 3-5 mL. SLNs were detected intraoperatively by visualization of blue dye, detection of radiolabeled colloid using a handheld gamma detection probe (Neoprobe; US Surgical Corp.), or both. A node was judged to be a SLN if it stained blue and/or had radioactivity.
Pathologic Assessment of Sentinel Nodes
Harvested SLNs were sectioned at 2-to 3-mm intervals along the short axis of the lymph node as previously described. 33 34 The median number of SLNs removed during SLND was 2 (range 1-10).
Study Variables
The study variables included preoperative clinicopathologic factors (age at diagnosis, biopsy method, histologic subtype, and reason for SLND [higher histologic grade, DCIS [2 cm, palpable tumor, microinvasion suspected on biopsy, or planned total mastectomy]) and postoperative clinicopathologic factors (estrogen receptor status, progesterone receptor status, evidence of microinvasive or invasive cancer on final pathology, and larger pathologic size of DCIS). Occult invasion was classified as microinvasive carcinoma (B1 mm in the greatest dimension) or invasive carcinoma ([1 mm in the greatest dimension) identified at the final pathology. 34 To evaluate the theory of benign mechanical transport of cells, variables that indicate the extent of preoperative tumor manipulation including total number of biopsies, surgeries, and interventions (total biopsies and surgeries performed before SLND) and total needle localizations were interrogated. All procedures performed in the breast within 6 months before SLND were recorded. For example, a patient who had undergone four biopsies or three biopsies plus partial mastectomy followed by total mastectomy and SLND was considered to have undergone four total interventions. The procedure performed in conjunction with the SLND was not counted toward the number of total interventions.
Statistical Analyses
The primary outcome was positive SLN findings. The secondary outcome was the clinical significance of positive SLN findings as evidenced by patient survival and changes in management such as completion ALND, nodal radiation therapy, or adjuvant chemotherapy.
Univariate analysis was performed to examine the association between variables and positive SLN findings using the v 2 test or Fisher's exact test for categorical variables and the Mann-Whitney U test for continuous variables. Variables with a P value lower than 0.25 were evaluated by multivariate analysis using the multiple logistic regression model after backward stepwise Wald elimination to identify independent predictors of positive SLN findings. Variables identified as independent predictors were subjected to within-response analysis to determine their individual contribution to specific subsets of positive SLN findings (ITCs and nodal metastases). Kaplan-Meier and actuarial methods were used to evaluate patient survival. A P value lower than 0.05 was considered significant. The statistical analyses were performed using SPSS software (version 15; SPSS, Inc., Chicago, IL, USA).
RESULTS
The median age of the study patients was 54 years. Most of the patients had their diagnosis determined by percutaneous biopsy (n = 975, 79 %) and were treated with total mastectomy (n = 948, 76.8 %). The majority of tumors were composed of more than one histologic subtype, and comedonecrosis was common (n = 896, 72.6 %). The estrogen receptor was positive in 74.3 % (n = 776/1044) of the patients tested, and the progesterone receptor was positive in 56 % (n = 582/1040). The reasons for performing SLND included high-grade disease (n = 622, 50.4 %), DCIS larger than 2 cm (n = 632, 51.2 %), a clinically palpable tumor (n = 160, 13.0 %), and microinvasion suspected on biopsy (n = 238, 19.3 %). Some patients had more than one reason for SLND. The median follow-up time was 61.7 months.
A positive SLN was identified in 132 patients (10.7 %): 66 patients with ITCs (5.4 %), 36 patients with micrometastases (2.9 %), and 30 patients with macrometastases (2.4 %). Of these patients, the majority (n = 114, 86.4 %) had positive SLN findings in a single SLN. A total of 327 patients (26.5 %) were upstaged to microinvasive (n = 68, 5.5 %) or invasive (n = 259, 21 %) cancer. The rate of upstaging depended on the biopsy method used, with 36 % (173/480) having small-bore percutaneous biopsy (needle size[11 gauge), 24 % (119/495) having large-bore percutaneous biopsy (needle size B11 gauge), and 13.5 % (35/259) having excisional biopsy. The probability of a positive SLN finding was correlated with the extent of invasion evident at the final pathology. Positive SLN findings occurred for 6.2 % (56/907) of the patients with pure DCIS, 16.2 % (11/68) of the patients with microinvasive cancer, and 25.1 % (65/259) of the patients with invasive cancer. The patients with pure DCIS had the lowest volume of SLN disease, with 4.9 % (44/ 907) having ITCs, 1.3 % (12/907) having micrometastases, and none having macrometastases. Among the patients with microinvasive cancer, 8.8 % (6/68) had ITCs, 4.4 % (3/68) had micrometastases, and 2.9 % (2/68) had macrometastses. Of the patients with invasive cancer, 6.2 % (n = 16/259) had ITCs, 8.1 % (n = 21/259) had micrometastases, and 10.8 % (n = 28/259) had macrometastases. Three patients with negative SLNs were found to have non-sentinel intramammary lymph node metastases and a final pathologic nodal stage of pN1a.
Various clinical and pathologic factors were examined to determine predictors of positive SLN findings (Table 1) . In the univariate analysis, the preoperative factors predictive of positive SLN findings included papillary histologic subtype, clinically palpable tumor, DCIS larger than 2 cm, and microinvasion suspected on biopsy. The total number of biopsies, total number of surgeries, and total number of interventions also correlated with positive SLN findings. The pathologic factors associated with positive SLN findings are shown in Table 2 . The within-response analysis of these factors demonstrated that excisional biopsy, DCIS larger than 2 cm, more than three total interventions, and occult invasion were predictive of ITCs, whereas only papillary histologic subtype and occult invasion remained predictive of SLN metastases.
We further examined the relationship between the total number of interventions and positive SLN findings by subdividing the cohort into patients with pure DCIS and patients with microinvasive or invasive cancer at the final pathology. The probability of positive SLN findings increased with the total number of interventions independent of whether the patient had pure DCIS or evidence of occult invasion (Fig. 1) . This phenomenon likely resulted from the association between an increasing number of interventions and a finding of ITCs (P \ 0.001) ( Table 2 ).
The impact of positive SLN findings on clinical management and patient survival is summarized in Table 3 . Of the 132 patients with positive SLN findings, 51 (38.6 %) had completion ALND (6 for ITCs and 45 for metastases). Additional positive nodes were identified by ALND in eight patients, all of whom had occult invasion and SLN metastases (1 micrometastasis, 7 macrometastases). The majority of the patients with SLN macrometastases (n = 27/30, 90 %) had a final pathologic nodal stage of pN1a. For the patients with positive SLN findings, adjuvant chemotherapy was administered more experienced few recurrence events. This group had two local recurrences (3 %), one regional recurrence (1.5 %), and no distant recurrences. We chose to use the total number of interventions rather than the total number of biopsies and the total number of surgeries in the final model because the first variable is a composite of the other two c Only variables found to be predictive of positive SLN findings were chosen for entry into the models for isolated tumor cells and metastases to determine their individual contributions Kaplan-Meier analysis showed that the patients who had pure DCIS with and without positive SLN findings experienced equivalent 5-year disease-free survival (DFS) rates (100.0 and 99.7 %, respectively; P = 0.679) (Fig. 2) . The 5-year DFS was 99.7 % for the patients with pure DCIS compared with 96.5 % for the patients with occult invasion (P \ 0.001). The patients who had occult invasion with positive SLN findings showed the lowest 5-year actuarial DFS (91.7 %; P \ 0.001). 
DISCUSSION
In this cohort of 1234 patients with an initial diagnosis of DCIS who underwent SLND, we found a 10.7 % (n = 132) incidence of positive SLN findings. Occult invasion in the primary tumor was identified in 327 patients (26.5 %). The independent predictors of positive SLN findings included excisional biopsy, papillary histologic subtype, DCIS larger than 2 cm, more than three interventions, and evidence of occult invasion. Of these predictors, more than three interventions and occult invasion were the strongest risk factors for positive SLN findings in patients with an initial diagnosis of DCIS.
The association of positive SLN findings with an increased number of interventions both for patients with pure DCIS and for patients with DCIS with occult invasion supports the theory of benign mechanical transport of breast epithelial cells due to manipulation of the primary tumor. The patients with ITCs in SLNs had a 100 % DFS at 5 years, with few changes in management (median followup period, 55.7 months). We also found that positive SLN findings were associated with a reduced 5-year DFS among patients with occult invasion but not among those with pure DCIS, suggesting that positive SLN findings have an impact on prognosis only if occult invasion is identified.
Despite the inherently low metastatic potential of DCIS, previous studies have reported positive SLNs in 1-22 % of patients with pure DCIS. Our rate of 6.2 % (ITCs in 4.9 % and metastases in 1.3 %) is consistent with rates in previous reports. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] The two largest series investigating SLND in pure DCIS to date (the series of Veronesi et al. 8 and Intra et al. from the European Institute of Oncology 35 ) showed respective SLN metastasis rates of 1.8 % (9/508) and 1.4 % (12/854). These rates are concordant with our findings. Intra et al., 35 however, reported a significantly lower ITC rate (0.8 %, 4/508) than the rate reported in our study, likely due to the less routine use of immunohistochemical analysis at their institution.
Our study identified occult invasion and more than three interventions as the strongest predictors of positive SLN findings in patients with DCIS. The relationship between occult invasion and increased risk of positive SLNs has been demonstrated previously. 36, 37 The theory of benign mechanical transport of cells secondary to preoperative biopsy, surgical excision, or tumor massage has been proposed as a potential source for positive nodal findings. [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] To our knowledge, however, the current study is the first to investigate the total number of interventions (total number of biopsies and surgeries before SLND) as a predictor of positive SLN findings. Our data suggest that an increasing number of interventions is associated with a higher incidence of positive SLN findings in DCIS. This finding may support the theory of benign mechanical transport of breast epithelial cells.
This study specifically sought to examine a cohort of patients with an initial diagnosis of DCIS undergoing SLND. Few studies have taken this approach. Most previous studies have chosen to investigate a more heterogeneous group of patients with an initial diagnosis of either DCIS or DCIS with microinvasion or have chosen to exclude patients with evidence of occult invasion at the final pathology. This latter patient group is not insubstantial and traditionally accounts for 10-25 % of patients with an initial diagnosis of DCIS depending on the biopsy method used. In fact, they accounted for 26.5 % of the patients in our study (36 % for small-bore percutaneous biopsy, 24 % for large-bore percutaneous biopsy, and 13.5 % for excisional biopsy).
We designed this study to mimic closely the decisionmaking process that clinicians face when treating patients with a presumptive diagnosis of DCIS because we sought to determine whether all, none, or a select group of patients with DCIS should undergo SLND. As demonstrated in our study, it is the select group of DCIS patients found to have evidence of occult invasion at the final pathology for whom positive SLN findings have an impact on prognosis and who thus may benefit from SLND and adjunct therapies. Although larger-bore percutaneous biopsy has decreased the rate of upstaging, it still does occur, and the question remains as to how patients at high risk for invasive disease can be identified to determine who will benefit from SLND. For patients undergoing breast-preserving surgery, one reasonable approach may be to avoid SLND unless invasive disease is discovered at the final pathology. This would save 66 % of patients undergoing breast-preserving surgery an unnecessary procedure and could reduce overall costs of treatment. Another approach is to avoid the use of immunohistochemical analysis of SLNs. This likely would reduce the finding of ITCs which can introduce difficulty in determining the need for ALND and systemic therapy for patients with pure DCIS.
Our study had certain limitations including its retrospective design and its inherent biases. Because this was a single-institution study, external validation is needed. Most of the patients in our series were treated with mastectomy due to large tumor size or extensive microcalcifications. We included only DCIS patients undergoing SLND and did not examine DCIS patients selected not to undergo SLND. Thus, we were unable to examine the possibility that the SLND procedure itself had an impact on the survival of patients with positive SLN findings. Using a propensity score-based analysis to compare survival between patients who do and those who do not undergo SLND could provide additional evidence regarding the utility of SLND in DCIS.
Overall, our study demonstrated that occult invasion and more than three interventions are the strongest risk factors for positive SLN findings in patients with an initial diagnosis of DCIS. This may support the theory of benign mechanical transport of breast epithelial cells. Positive SLN findings appear to have an impact on prognosis only when occult invasion is present in the final resected specimen, suggesting that routine use of SLND for patients with DCIS is not warranted except for patients at high risk for invasive disease.
